First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer.
Fulvestrant;RLY-2608
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer. ### Output: Fulvestrant;RLY-2608